Lipoprotein apheresis 58 items
The German experience from 2008 onward, five- and twelve-year follow-up, and pelacarsen as its replacement.
Trials, agents, guidance
- Trial Lp(a)FRONTIERS APHERESIS
- Agent Lipoprotein apheresis
Studies
- Lp(a)FRONTIERS APHERESIS: pelacarsen replaces lipoprotein apheresis in 25 of 26 patients (Parhofer et al., EHJ 2026)
- Lipoprotein apheresis cuts event rates in Lp(a) hyperlipoproteinaemia with progressive disease (Leebmann et al., Circulation 2013)
- Five years of lipoprotein apheresis for Lp(a)-associated disease: the German prospective follow-up (Roeseler et al., ATVB 2016)
- Twelve years of lipoprotein apheresis for Lp(a)-associated progressive ASCVD: Pro(a)LiFe (Klingel et al., Atherosclerosis 2025)
- Lp(a)-lowering therapies: a promising future (Zhang, Navar, Tokgozoglu, EHJ 2026)
- Lp(a) and its significance in cardiovascular disease: a review (Duarte Lau and Giugliano, JAMA Cardiol 2022)
- The Australian Atherosclerosis Society issues a position statement recommending selective, not universal, Lp(a) screening for intermediate-to-high-risk patients (Heart Lung Circ 2023)
- A practical roadmap for managing elevated Lp(a) today, from apheresis's 60-75% cut to RNA agents' 80-95%, while outcomes trials are pending (Semin Thromb Hemost 2025)
- Long-term lipoprotein apheresis cuts cardiovascular events by 72% in 25 patients with isolated elevated Lp(a), followed a mean 7.1 years (J Clin Lipidol 2024)
- Lipoprotein apheresis improves clot formation and fibrinolysis markers in refractory angina patients with high Lp(a), a randomised crossover trial of 20 patients (J Clin Lipidol 2019)
- Antisense therapy can cut Lp(a) by up to 90% in phase 1/2 trials, as three treatment approaches converge on the 'revenant' lipoprotein, a review (Eur Heart J 2017)
- Lipoprotein apheresis improves myocardial perfusion and plaque burden in refractory angina patients with high Lp(a), a randomised crossover trial of 20 patients (Eur Heart J 2017)
- Niacin lowers oxidized phospholipids and Lp(a), but statins raise both by over 20%, a study of 591 patients plus a review of 12 trials and 3896 patients (J Clin Lipidol 2016)
- Only apheresis is FDA-approved for Lp(a) today, review of the RNA-therapeutics pipeline moving to phase 3 outcomes trials (J Clin Lipidol 2026)
- Managing progressive ASCVD in patients with elevated Lp(a) despite optimal LDL-C control, review (Anatol J Cardiol 2026)
- The impact of lipid apheresis on changes of lipoprotein(a): a systematic review and meta-analysis
- Chronic lipoprotein apheresis progresses aortic valve stenosis at a similar rate whether or not Lp(a) is elevated, 47-patient follow-up finds (Endocrine 2025)
- Lipoprotein apheresis remains the only approved Lp(a)-specific option for peripheral artery disease patients with elevated Lp(a), review finds (Curr Opin Lipidol 2025)
- Apheresis cuts Lp(a) by 75% and the CETP inhibitor obicetrapib by 40%, but a 100 mg/dL reduction is needed to match LDL-C's mortality benefit, review calculates (Nutr Metab Cardiovasc Dis 2025)
- Lipoprotein apheresis removes cell-derived extracellular vesicles alongside Lp(a), a possible extra mechanism behind its benefit (Sci Rep 2024)
- A single apheresis session immediately clears over 60% of atherogenic apoB particles, remaining the mainstay treatment for FH and elevated Lp(a), a review (Curr Atheroscler Rep 2023)
- Statins raise Lp(a) while PCSK9 inhibitors and RNA therapies lower it, a 57-year literature review of pharmacological effects on Lp(a) (Endocr Pract 2023)
- PCSK9 inhibitors and apheresis are the only current Lp(a)-lowering options proven to also cut cardiovascular risk, while ASOs and siRNAs may exceed 70% reduction, a review (Atherosclerosis 2022)
- Over 20% of the population has Lp(a) above 50 mg/dL, and antisense oligonucleotides can cut it by up to 90% as the Lp(a)HORIZON outcomes trial nears results, a review (Curr Atheroscler Rep 2021)
- APO(a)Lrx (pelacarsen) can cut Lp(a) by up to 80%, far surpassing PCSK9 inhibitors, in patients where Lp(a) explains 5-20% of suspected FH diagnoses, a review (J Clin Med 2020)
- Lipoprotein apheresis lowers macrophage cholesterol-loading capacity alongside Lp(a), an Italian case-control study of 34 patients with two novel LPA variants (J Clin Lipidol 2020)
- Lp(a) above 50 mg/dL raises cardiovascular risk, above 180 mg/dL matches familial hypercholesterolaemia, a review 57 years after Lp(a) discovery (Prog Cardiovasc Dis 2020)
- A single apheresis session cuts LDL and Lp(a) by about 65%, a review of apheresis for severe hypercholesterolaemia and elevated Lp(a) (Pathology 2019)
- Lipoprotein apheresis cuts major cardiovascular events by 94% in US patients with high Lp(a) and normal LDL, a retrospective cohort of 14 patients (J Clin Lipidol 2019)
- Lp(a) above 200 mg/L raises cardiovascular risk through both atherogenic and thrombotic pathways, a review of Lp(a) molecular mechanisms (Prague Med Rep 2019)
- Apheresis lowers Lp(a) by over 60%, while a phase 1 antisense drug reaches 88.8%, a review of Lp(a)-lowering options (Atheroscler Suppl 2017)
- Apheresis remains the only option for very high Lp(a) since no drug lowers it without affecting other lipids, a review of Lp(a)-lowering treatments (Curr Med Chem 2017)
- Antisense drug IONIS-APO(a)Rx cuts Lp(a) by about 80%, a review of apolipoprotein(a) antisense oligonucleotides (Curr Pharm Des 2017)
- Lp(a)-lowering therapies range from 20% modest to 80% dramatic reductions, a review of emerging options for cardiovascular prevention (Curr Atheroscler Rep 2016)
- The only controlled trial of Lp(a)-specific apheresis showed plaque regression after 18 months, a review of Lp(a) apheresis (Curr Opin Lipidol 2016)
- A single apheresis session cuts Lp(a) by 60-75%, a review of lipoprotein apheresis for elevated Lp(a) (J Lipid Res 2016)
- Apheresis cuts cardiovascular events by more than 80% in patients with elevated Lp(a), a review of lipoprotein apheresis and its future alongside PCSK9 inhibitors and antisense drugs (Med Devices (Auckl) 2016)
- A randomised sham-controlled crossover trial will test whether apheresis helps refractory angina patients with high Lp(a), a study protocol (Atheroscler Suppl 2015)
- Apheresis remains the only proven Lp(a)-lowering therapy in Europe, cutting levels by 60-70% per session, a review of current treatment options (Atheroscler Suppl 2015)
- Lipoprotein apheresis: From familial hypercholesterolemia and elevated lipoprotein(a) to emerging roles in peripheral arterial and renal disease
- Lp(a) affects 20% of the population, review of biology, guidelines and the emerging therapy pipeline (Eur Heart J Suppl 2026)
- Elevated Lp(a) amplifies peripheral arterial disease risk and worsens outcomes, but apheresis remains the only approved lowering option, review finds (Rev Cardiovasc Med 2025)
- An isoform-insensitive Lp(a) assay correlates well with traditional polyclonal methods in apheresis patients, pilot study argues for standardisation (J Clin Apher 2025)
- Combined lipoprotein apheresis and hemodialysis cut cardiovascular events by 57% in 9 patients with severe cardiovascular disease and end-stage renal disease (J Clin Apher 2025)
- Lipoprotein apheresis reduces oxidative susceptibility of both Lp(a) and LDL particles, a possible mechanism behind its cardiovascular benefit (Int J Mol Sci 2024)
- Lipoprotein apheresis transiently depletes very-long-chain fatty acids for at least 7 days, with lasting effects after a year of regular treatment, in 28 patients (J Clin Lipidol 2024)
- PCSK9 inhibitors modestly lower Lp(a) with cardiovascular benefit independent of LDL-C, while apheresis remains the most effective option, a review of modern approaches (Biomedicines 2021)
- Apheresis remains the most effective Lp(a) treatment while antisense oligonucleotides show promise in phase 2 trials, a review from physiopathology to therapy (Biomedicines 2021)
- Antisense apo(a) inhibitors could pair with statins for patients with both high Lp(a) and high LDL, as phase 3 data approaches, a review (Eur J Intern Med 2020)
- Lp(a) is genetically fixed and diet-resistant, a review of its biology and response to statins, apheresis, PCSK9 and CETP inhibitors and antisense drugs (J Mol Cell Cardiol 2019)
- Lp(a) apheresis may reduce limb events in peripheral arterial disease as effectively as it reduces coronary events, a review (Clin Res Cardiol Suppl 2019)
- Ten studies confirm lipoprotein apheresis lowers Lp(a) and cardiovascular events, a critical literature review (Blood Transfus 2016)
- Recurrent in-stent restenosis with markedly elevated Lp(a) and no other risk factors leads to a rare lipid disorder diagnosis and apheresis, case report finds (Eur Heart J Case Rep 2025)
- A patient with Lp(a) 3.5 times the FH average developed clotting during apheresis, a case report (J Clin Lipidol 2016)
- LDL apheresis halted coronary disease progression in a 50-year-old with refractory angina and high Lp(a), a case report (J Clin Lipidol 2012)